Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036480 | 1.00 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL5392736 | 0.88 | ALDH1A1 (0.51) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL5392742 | 0.88 | ALDH1A1 (0.51) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL6169631 | 0.88 | MAPT (0.48) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL6169905 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL6169914 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL6169288 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL6169292 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL3167942 | 0.80 | MAPT (0.49) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL6170877 | 0.80 | JUN (0.53) | ALDH1A1MAPTKDM4EHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513800-B1 | N-BENZOYLUREIDOCINNAMATE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-7049341-B2 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-05-23 | — | — | US | disclosed |
| EP-1513800-A1 | N-BENZOYLUREIDOCINNAMATE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | AVENTIS PHARMA AG (DE) | 2004-05-27 | — | — | US | disclosed |
| WO-2003104188-A1 | N-BENZOYLUREIDOCINNAMATE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102518-A1 | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use | SLC5A1, NQO1, SLC5A2 | ALDH1A1 230/4885MAPT 4812/4885KDM4E 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.